ZLAB
Zai Lab Ltd

1,226
Mkt Cap
$2.02B
Volume
714,098.00
52W High
$44.34
52W Low
$16.82
PE Ratio
-9.34
ZLAB Fundamentals
Price
$18.20
Prev Close
$18.09
Open
$18.41
50D MA
$20.50
Beta
1.19
Avg. Volume
831,547.23
EPS (Annual)
-$2.60
P/B
2.65
Rev/Employee
$213,583.80
Loading...
Loading...
News
all
press releases
Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO (repotrectinib) for Patients with NTRK-Positive Solid Tumors
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that Chinas National Medical Products Administration (NMPA) has approved the supplemental New Drug Application (sNDA) for AUGTYRO...
Business Wire·16h ago
News Placeholder
More News
News Placeholder
Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Companys senior management team will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday...
Business Wire·2d ago
News Placeholder
Zai Lab (NASDAQ:ZLAB) Insider Rafael Amado Sells 10,787 Shares
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) insider Rafael Amado sold 10,787 shares of the stock in a transaction that occurred on Wednesday, December 31st. The shares were sold...
MarketBeat·4d ago
News Placeholder
Zai Lab (NASDAQ:ZLAB) Shares Gap Up - Time to Buy?
Zai Lab (NASDAQ:ZLAB) Shares Gap Up - Still a Buy...
MarketBeat·14d ago
News Placeholder
Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that Chinas National Medical Products Administration (NMPA) approved the New Drug Application (NDA) for COBENFY (xanomeline and trospium...
Business Wire·15d ago
News Placeholder
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Rating of "Moderate Buy" from Brokerages
Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) have received an average recommendation of "Moderate Buy" from the eight research firms that are covering the company...
MarketBeat·16d ago
News Placeholder
Zai Lab (NASDAQ:ZLAB) Hits New 1-Year Low - Should You Sell?
Zai Lab (NASDAQ:ZLAB) Sets New 1-Year Low - Here's What Happened...
MarketBeat·29d ago
News Placeholder
Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the dosing of the first participant in a global Phase 1/1b clinical trial evaluating the safety, tolerability, pharmacokinetics, and...
Business Wire·30d ago
News Placeholder
Zai Lab Announces Updates to Chinas National Reimbursement Drug List
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the following medicines and indications have been renewed in the 2025 National Reimbursement Drug List (NRDL) released by Chinas...
Business Wire·1mo ago
News Placeholder
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Average Recommendation of "Moderate Buy" by Brokerages
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) has earned an average rating of "Moderate Buy" from the eight ratings firms that are covering the firm, MarketBeat Ratings reports. One...
MarketBeat·1mo ago
<
1
2
...
>

Latest ZLAB News

View

Advertisement|Remove ads.

Advertisement|Remove ads.